The Coretec Group Inc. (CRTG) 10-Q 31 Oct 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Document Information [Line Items]
Entity Central Index Key	0001375195
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	000-54697
Entity Registrant Name	THE CORETEC GROUP INC.
Entity Incorporation, State or Country Code	OK
Entity Tax Identification Number	73-1479206
Entity Address, Address Line One	600 S. Wagner Rd
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48103
City Area Code	866
Local Phone Number	916-0833
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		267,556,422

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 2,776,077	$ 4,053,327
Prepaid expenses	129,720	133,491
Total current assets	2,905,797	4,186,818
Property and equipment, net	75,835	0
Other assets:
Intangibles, net	927,632	989,604
Goodwill	166,000	166,000
Deposits-other	4,550	16,343
Total other assets	1,098,182	1,171,947
Total Assets	4,079,814	5,358,765
Current liabilities:
Notes payable	91,498	0
Accounts payable and accrued expenses	303,068	307,096
Total current liabilities	394,566	307,096
Long term debt, net	1,398,560	1,187,518
Total Liabilities	1,793,126	1,494,614
Stockholders' equity:
Preferred stock, Series A convertible, $0.0002 par value, 500,000 shares authorized; 345,000 shares issued and outstanding at September 30, 2022 and December 31, 2021	69	69
Common stock $0.0002 par value, 1,500,000,000 shares authorized; 257,256,422 and 254,055,581 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.	51,449	50,809
Additional paid-in capital	17,435,148	17,295,262
Accumulated deficit	(15,199,978)	(13,481,989)
Total Stockholders' Equity	2,286,688	3,864,151
Total Liabilities and Stockholders' Equity	$ 4,079,814	$ 5,358,765

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited)-parentheticals (Parentheticals) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0002	$ 0.0002
Preferred Stock, Shares Authorized (in shares)	500,000	500,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	345,000	345,000
Preferred Stock, Shares Issued (in shares)	345,000	345,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0002	$ 0.0002
Common Stock, Shares Authorized (in shares)	1,500,000,000	1,500,000,000
Common Stock, Shares, Issued (in shares)	257,256,422	254,055,581
Common Stock, Shares, Outstanding, Ending Balance (in shares)	257,256,422	254,055,581

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income:
Revenue	$ 0	$ 0	$ 0	$ 0
Expenses:
Research and development	80,167	192,255	400,524	428,251
General and administrative	301,004	2,480,697	1,172,463	5,340,325
Interest	52,831	44,077	148,273	175,015
Total expenses	434,002	2,717,029	1,721,260	5,943,591
Other income	2,324	45,124	3,271	45,124
Net loss	$ (431,678)	$ (2,671,905)	$ (1,717,989)	$ (5,898,467)
Loss per share:
Basic and diluted (in dollars per share)	$ (0.002)	$ (0.011)	$ (0.007)	$ (0.024)
Weighted average shares outstanding, basic and diluted (in shares)	256,912,934	251,965,750	255,923,378	235,063,138

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Total
Balance (in shares) at Dec. 31, 2020		345,000		213,751,145
Balance at Dec. 31, 2020	$ 0	$ 69	$ 0	$ 42,750	$ (988,900)	$ 8,033,313	$ 126,125	$ (7,339,175)	$ (862,775)	$ 736,957
Options issued for compensation and services		$ 0		$ 0		18,723		0		18,723
Common stock issued for liabilities (in shares)		0		1,716,447
Common stock issued for liabilities		$ 0		$ 343		69,921		0		70,264
Exchange of stock options for common stock (in shares)		0		1,200,000
Exchange of stock options for common stock		$ 0		$ 240		(240)		0		0
Net loss for the period		0		0		0		(438,422)		(438,422)
Warrants issued		0		0		62,785		0		62,785
Debt converted to common stock		$ 0		$ 304		49,696		0		50,000
Debt converted to common stock (in shares)		0		1,519,757
Private placement stock issuance (in shares)		0		23,500,000
Private placement stock issuance		$ 0		$ 4,700		4,908,500		0		4,913,200
Balance (in shares) at Mar. 31, 2021		345,000		241,687,349
Balance at Mar. 31, 2021		$ 69		$ 48,337		12,153,798		(7,651,472)		4,550,732
Balance (in shares) at Dec. 31, 2020		345,000		213,751,145
Balance at Dec. 31, 2020	$ 0	$ 69	$ 0	$ 42,750	$ (988,900)	8,033,313	$ 126,125	(7,339,175)	$ (862,775)	736,957
Net loss for the period										(5,898,467)
Debt converted to common stock										230,000
Balance (in shares) at Sep. 30, 2021		345,000		252,285,754
Balance at Sep. 30, 2021		$ 69		$ 50,456		17,216,935		(13,111,517)		4,155,943
Balance (in shares) at Mar. 31, 2021		345,000		241,687,349
Balance at Mar. 31, 2021		$ 69		$ 48,337		12,153,798		(7,651,472)		4,550,732
Options issued for compensation and services		$ 0		$ 0		2,340,723		0		2,340,723
Common stock issued for liabilities (in shares)		0		3,327,280
Common stock issued for liabilities		$ 0		$ 665		322,645		0		323,310
Exchange of stock options for common stock (in shares)		0		900,000
Exchange of stock options for common stock		$ 0		$ 180		(180)		0		0
Net loss for the period		0		0		0		(2,788,140)		(2,788,140)
Debt converted to common stock		$ 0		$ 1,094		178,906		0		180,000
Debt converted to common stock (in shares)		0		5,471,125
Balance (in shares) at Jun. 30, 2021		345,000		251,385,754
Balance at Jun. 30, 2021		$ 69		$ 50,276		14,995,892		(10,439,612)		4,606,625
Options issued for compensation and services		$ 0		$ 0		2,221,223		0		2,221,223
Exchange of stock options for common stock (in shares)		0		900,000
Exchange of stock options for common stock		$ 0		$ 180		(180)		0		0
Net loss for the period		$ 0		$ 0		0		(2,671,905)		(2,671,905)
Balance (in shares) at Sep. 30, 2021		345,000		252,285,754
Balance at Sep. 30, 2021		$ 69		$ 50,456		17,216,935		(13,111,517)		4,155,943
Balance (in shares) at Dec. 31, 2021		345,000		254,055,581
Balance at Dec. 31, 2021		$ 69		$ 50,809		17,295,262		(13,481,989)		3,864,151
Options issued for compensation and services		$ 0		$ 0		70,973		0		70,973
Common stock issued for liabilities (in shares)		0		660,210
Common stock issued for liabilities		$ 0		$ 132		17,166		0		17,298
Exchange of stock options for common stock (in shares)		0		900,000
Exchange of stock options for common stock		$ 0		$ 180		(180)		0		0
Net loss for the period		$ 0		$ 0		0		(679,342)		(679,342)
Balance (in shares) at Mar. 31, 2022		345,000		255,615,791
Balance at Mar. 31, 2022		$ 69		$ 51,121		17,383,221		(14,161,331)		3,273,080
Balance (in shares) at Dec. 31, 2021		345,000		254,055,581
Balance at Dec. 31, 2021		$ 69		$ 50,809		17,295,262		(13,481,989)		$ 3,864,151
Exchange of stock options for common stock (in shares)										900,000
Net loss for the period										$ (1,717,989)
Debt converted to common stock										0
Balance (in shares) at Sep. 30, 2022		345,000		257,256,422
Balance at Sep. 30, 2022		$ 69		$ 51,449		17,435,148		(15,199,978)		2,286,688
Balance (in shares) at Mar. 31, 2022		345,000		255,615,791
Balance at Mar. 31, 2022		$ 69		$ 51,121		17,383,221		(14,161,331)		3,273,080
Options issued for compensation and services		$ 0		$ 0		18,723				18,723
Common stock issued for liabilities (in shares)		0		867,782
Common stock issued for liabilities		$ 0		$ 174		20,393		0		20,567
Net loss for the period		$ 0		$ 0		0		(606,969)		(606,969)
Balance (in shares) at Jun. 30, 2022		345,000		256,483,573
Balance at Jun. 30, 2022		$ 69		$ 51,295		17,422,337		(14,768,300)		2,705,401
Common stock issued for liabilities (in shares)		0		772,849
Common stock issued for liabilities		$ 0		$ 154		8,710		0		8,864
Net loss for the period		0		0		0		(431,678)		(431,678)
Warrants issued		$ 0		$ 0		4,101		0		4,101
Balance (in shares) at Sep. 30, 2022		345,000		257,256,422
Balance at Sep. 30, 2022		$ 69		$ 51,449		$ 17,435,148		$ (15,199,978)		$ 2,286,688

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)-parentheticals - shares	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022
Preferred Stock [Member] | Series A Preferred Stock [Member]
Debt converted to common stock (in shares)					0	0
Common stock issued for liabilities (in shares)	0	0	0		0	0
Exchange of stock options for common stock (in shares)			0	0	0	0
Exchange of stock options for common stock (in shares)							900,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows from Operating Activities
Net loss	$ (1,717,989)	$ (5,898,467)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	4,430	0
Amortization - patents and other intangibles	61,972	60,772
Amortization - debt discount	45,394	73,720
Options issued for compensation and services	89,696	4,580,669
Change in:
Prepaid expenses	(105,215)	(52,363)
Deposits	(11,793)	(11,750)
Accounts payable and accrued liabilities	42,701	308,779
Net cash used in operating activities	(1,356,788)	(810,414)
Cash Flows from Investing Activities
Capitalized website costs	0	12,007
Purchases of equipment	80,265	0
Net cash used in investing activities	(80,265)	(12,007)
Cash Flows from Financing Activities
Repayments of Notes Payable	(9,946)	(90,505)
Proceeds from debt and warrants issued	169,749	334,651
Proceeds from private placement stock issued	0	4,913,200
Net cash provided by financing activities	159,803	5,157,346
Net change in cash	(1,277,250)	4,334,925
Cash, beginning of period	4,053,327	22,219
Cash, end of period	2,776,077	4,357,144
Supplemental Disclosure of Cash flow Information
Cash paid during the period for interest	106,783	92,434
Non-Cash Financing Activities
Debt converted to common stock	0	230,000
Stock options exchanged for common stock	180	600
Common stock issued to satisfy liabilities	$ 46,729	$ 393,574

Note 1 - Business Organization,

Note 1 - Business Organization, Nature of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 Business Organization, Nature of Business and Basis of Presentation Nature of Business The Coretec Group Inc. (the “Group”) (formerly 3DIcon Corporation) (“3DIcon”) was incorporated on August 11, 1995, under the laws of the State of Oklahoma as First Keating Corporation. The articles of incorporation were amended August 1, 2003 to change the name to 3DIcon Corporation. During 2001, First Keating Corporation began to focus on the development of 360-degree holographic technology. From January 1, 2001, 3DIcon’s primary activity has been the raising of capital in order to pursue its goal of becoming a significant participant in the development, commercialization and marketing of next generation 3D display technologies. Coretec Industries, LLC (“Coretec”), a wholly owned subsidiary of the Group (collectively the “Company”), was organized on June 2, 2015 in the state of North Dakota. Coretec is currently developing, testing, and providing new and/or improved technologies, products, and service solutions for energy-related industries including, but not limited to oil/gas, renewable energy, and distributed energy industries. Many of these technologies and products also have application for medical, electronic, photonic, display, and lighting markets among others. Early adoption of these technologies and products is anticipated in markets for energy storage (Li-ion batteries), renewable energy (BIPV), and electronics (Asset Monitoring). Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The Company believes that the disclosures made are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company’s year-end audited consolidated financial statements and related footnotes included in the previously filed Form 10-K, and in the opinion of management, reflects all adjustments necessary to present fairly the consolidated financial position of the Company. The consolidated results of operations for interim periods may not be indicative of the results which may be realized for the full year.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 2 Summary of Significant Accounting Policies Principles of Consolidation The condensed consolidated financial statements include the accounts of the Group and its wholly owned subsidiary, Coretec. Intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used. Property and Equipment Property and equipment is recorded at cost. Depreciation is recorded over the estimated useful lives using the straight-line method. Maintenance and repairs are expensed as incurred; major improvements and betterments are capitalized. Intangibles Intangible assets consist of patents and capitalized website costs. Intangible assets are recorded at cost (or fair value as of the date of acquisition in business combinations), and intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Goodwill The Company evaluates the carrying value of goodwill on an annual basis and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of goodwill below its carrying amount. When assessing whether goodwill is impaired, management considers first a qualitative approach to evaluate whether it is more likely than not the fair value of the goodwill is below its carrying amount; if so, management considers a quantitative approach by analyzing changes in performance and market-based metrics as compared to those used at the time of the initial acquisition. For the periods presented, no impairment charges were recognized. Impairment of Long-Lived Assets Long-lived assets, such as property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Fair Value of Financial Instruments The following methods and assumptions were used to estimate the fair value of each class of financial instrument held by the Company: Current assets and current liabilities Notes payable Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2022 2021 Options 53,158,160 53,711,609 Warrants 142,814,000 142,604,000 Series A convertible preferred stock 115,000 115,000 Convertible debt 45,155,537 40,914,134 Total potentially dilutive shares 241,242,697 237,344,743 Research and Development Research and development costs are expensed as incurred. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the condensed consolidated financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the consolidated financial statements, except as disclosed in Note 6. Income Taxes The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in tax laws or rates. The effect on deferred tax assets and liabilities of a change in tax rates will be recognized as income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company’s tax benefits are fully offset by a valuation allowance due to the uncertainty that the deferred tax assets would be realized. Management considers the likelihood of changes by taxing authorities in its filed income tax returns and recognizes a liability for or discloses potential changes that management believes are more likely than not to occur upon examination by tax authorities. Management has not identified any uncertain tax positions in filed income tax returns that require recognition or disclosure in the accompanying consolidated financial statements. Recent Accounting Pronouncements The following is a summary of recent accounting pronouncement recently adopted by the Company: In May 2021, the FASB issued ASU 2021-04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options

Note 3 - Intangibles

Note 3 - Intangibles	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 3 Intangibles The following table sets forth patents: September 30, December 31, Patents 2022 2021 Gross Carrying Amount $ 1,400,000 $ 1,400,000 Accumulated Amortization (481,375 ) (421,203 ) $ 918,625 $ 978,797 The patents were obtained with the September 30, 2016 reverse acquisition of the 3DIcon Corporation. Amortization expense for the next five fiscal years and thereafter is expected to be approximately $80,000 annually through the year ended December 31, 2034. Intangible assets include $12,007 of capitalized website costs during 2021. Accumulated amortization was $3,000 and $1,200 as of September 30, 2022 and December 31, 2021, respectively. Amortization expense for the next four fiscal years is expected to be approximately $2,400, annually.

Note 4 - Notes Payable

Note 4 - Notes Payable	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 Notes Payable The following table sets forth the notes payable: September 30, December 31, 2022 2021 Notes payable: 5.26% Insurance premium finance agreement due June 2023 $ 91,498 $ - Notes payable - current $ 91,498 $ - Long term debt: 10% Promissory note due January 2024 $ 1,485,617 $ 1,310,617 Less: Warrants issued (63,684 ) (93,929 ) Debt issue costs (23,373 ) (29,171 ) Total long term debt $ 1,398,560 $ 1,187,518 5.26% Insurance premium finance agreement, due by June 2023 The Company entered into an insurance financing agreement in August 2022 totaling $101,444. The monthly payments under the agreement are due in ten 10% Promissory note due January net On October 4, 2019, the Company entered into a Credit Agreement and related Promissory Note with Diversified Alpha Fund of Navigator Global Fund Manager Platform SPC (“DAF”), the Lender. DAF is a segregated portfolio fund of Navigator Global Fund Manager Platform SPC. DAF is managed and controlled by Mollitium Investment Management (Mollitium). Mollitium utilizes Diversified Global Investment Advisors Ltd. (“DGIA”) to act in an advisory role. DGIA maintains an Investment Committee to support the services to Mollitium. Simon Calton serves as part of this five-member investment committee and in accordance with the investment committee’s guidelines, Mr. Calton does not participate in matters or voting that pertain to the Company due to his conflict of interest. Investment advice provided by DGIA to Mollitium are recommendations only and the final decision on actions are the responsibility of Mollitium. Carlton James Global Management, Ltd (CJGM) serves as a distributer of investments by introducing funds available to the market of which DAF is included in CJGM’s group of funds. Compensation to CJGM occurs when investments are made into funds that they introduce. CJGM is part of the Carlton James Group of which Mr. Calton is CEO. The 10% Promissory Note, in a principal amount of $2,500,000, is due on the 15th day of the 4th anniversary of each advance with the first capital payment due on March 15, 2024. The Promissory Note has attached warrants to subscribe for and purchase 3,000,000 shares of common stock at an exercise price of $0.052 per share. Under the terms of the Credit Agreement, DAF will fund the Promissory Note in sixteen (16) On November 16, 2021, the Company countersigned a letter of variation (the “Variation”) to the credit agreement entered into, on October 4, 2019, with DAF. Pursuant to the Variation, the Lender agreed to extend the repayment days for each advance made by Lender under the credit agreement until the fourth anniversary of such advance. DAF also communicated to the Company that interest only payments would be due on a quarterly basis, effective January of 2022. Under the terms of the Promissory Note, DAF has the right to elect to convert all or part of the Promissory Notes at a price equal to seventy percent (70%) (15) Under the terms of the Credit Agreement, warrants to subscribe for and purchase 3,000,000 shares of common stock at an exercise price of $0.052 per share were issued to DAF. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrants. As of September 30, 2022, 2,814,000 warrants have been granted under the terms of the DAF Credit Agreement. There were 210,000 warrants issued under the Credit Agreement during the nine months ended September 30, 2022. The allocated cost of the warrants amounted to $4,101 and $62,784 during the nine months ended September 30, 2022 and the year ended December 31, 2021. The allocated cost of the warrants is amortized over the life of the debt, with $34,346 and $35,358 amortized during the nine months ended September 30, 2022 and 2021, respectively. Additionally, under the terms of the Credit Agreement, the Company agreed to pay a commitment fee of 3% of each advance and reimburse DAF for certain expenses in connection with the preparation, interpretation, performance and enforcement of the Credit Agreement. Those costs amounted to $5,250 and $10,350 for nine months ended September 30, 2022 and the year ended December 31, 2021. Those costs are being amortized over the life of the debt. The Company amortized $11,048 and $11,978 during the nine months ended September 30, 2022 and 2021, respectively.

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5 Commitments and Contingencies Warrants Warrants to subscribe for and purchase up to 3,000,000 shares of common stock at an exercise price of $0.052 per share were included under the terms of the DAF Credit Agreement. The warrants will be issued in amounts of 150,000 and 210,000 per month during the funding period. In the event that funding advances deviate from the planned schedule then warrants will be issued pro-rata at 1.2 warrants for every $1 of funding. Warrants granted under the terms of the DAF Credit Agreement as of September 30, 2022 total 2,814,000. The estimated value of the warrants granted monthly, with each advance, is calculated using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the warrant is based on historical exercise behavior and expected future experience. The resulting estimated value of the warrant is used to proportionally allocate the fair value of the debt advance and the fair value of the warrants. On March 2, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor in a private placement to sell (i) 23,500,000 shares of its common stock, (ii) pre-funded warrants to purchase up to an aggregate of 51,500,000 shares of its common stock, and (iii) warrants to purchase up to an aggregate of 82,500,000 shares of its common stock for gross proceeds of approximately $6,000,000. The combined purchase price for one share of common stock and associated Warrant is $0.08 and for one Pre-Funded Warrant and associated Warrant is $0.0799. The sale of the securities under the Purchase Agreement closed on March 5, 2021. The pre-funded warrants have an exercise price of $0.0001 per share, subject to adjustment as set forth in the pre-funded warrants for stock splits, stock dividends, recapitalizations and similar events. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. In addition, the Company agreed to issue to the placement agent (or its designees) warrants to purchase a number of shares equal to 8.0% of the aggregate number of shares and pre-funded warrant shares sold under the Purchase Agreement, or warrants to purchase an aggregate of up to 6,000,000 shares. The placement agent warrants generally will have the same terms as the warrants, except they will have an exercise price of $0.10. Warrants Summary The following table summarizes the Company’s warrants as of September 30, 2022: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2021 142,604,000 $ 0.0515 Granted 210,000 0.0520 Outstanding, September 30, 2022 142,814,000 $ 0.0515 3.89 $ 1,333,850 Options Stock options for employees, directors or consultants are valued at the date of award, which does not precede the approval date, and compensation cost is recognized in the period the options are vested. Stock options generally become exercisable on the date of grant and expire based on the terms of each grant. The estimated fair value of options for common stock granted is determined using the Black-Scholes option pricing model. The expected dividend yield is based on the average annual dividend yield as of the grant date. Expected volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury Constant Maturity rates as of the grant date. The expected life of the option is based on historical exercise behavior and expected future experience On June 8, 2020, the Board of Directors consented to a share exchange agreement with holders of 21,500,000 options awarded on August 7, 2019. The agreement allows for holders to exchange their options for rule 144 common stock at an exchange rate of 0.6 shares per 1 option. The modification of these options did not result in any additional compensation because there was no change in the fair value. During the nine months ended September 30, 2022, 1,500,000 options were exchanged for 900,000 shares that were issued under the executed exchange agreement. On March 23, 2022 the Company granted 950,000 options at an average grant date fair value of $0.055 determined using the Black-Scholes option pricing model. The options were granted to an employee and independent contractor for the Company. The following table summarizes the Company’s option activity during the nine-month period ended September 30, 2022: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2021 53,711,609 $ 0.093 Options granted 950,000 0.055 Options expired (3,449 ) 70.260 Exchanged for common stock (1,500,000 ) 0.041 Outstanding, September 30, 2022 53,158,160 $ 0.089 3.48 $ - Exercisable, September 30, 2022 53,158,160 $ 0.089 3.48 $ - The following table summarizes the Company’s options as of September 30, 2022: Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 0.041 12,500,000 1.85 12,500,000 $ 0.055 950,000 4.48 950,000 $ 0.065 1,000,000 2.75 1,000,000 $ 0.105 38,500,000 4.00 38,500,000 $ 0.240 208,160 4.47 208,160 Total 53,158,160 3.48 53,158,160 Litigation, Claims, and Assessments The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In the opinion of management, such matters are currently not expected to have a material impact on the Company’s condensed consolidated financial statements. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Leases The Company is headquartered in Ann Arbor, Michigan where it is leasing office space and a wet laboratory in the same facility, under gross lease terms. On December 14, 2021, the Company entered into an annual lease for a wet laboratory. The annual rent obligation is $12,600 payable in equal monthly installments. The Company began using the wet laboratory space in March of 2022. On May 1, 2022 the Company entered into an annual lease for dedicated office space. The annual office rent obligation is $42,000 payable in equal monthly installments. Rent expense for the operating leases was $29,952 and $11,340 for the nine months ended September 30, 2022 and 2021, respectively.

Note 6 - Subsequent Events

Note 6 - Subsequent Events	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 6 Subsequent Events On October 14, 2022, the Company granted options to purchase a total of 24,000,000 shares of the Company’s common stock at an exercise price of $0.0277 per share. The options are exercisable for a period of five On October 18, 2022 the Company announced the appointment of Matthew Hoffman to Chief Operating Officer and full-time employee of the Company. Mr. Hoffman will retain his role as Chief Financial Officer and Corporate Secretary. In connection with Mr. Hoffman’s appointment as Chief Operating Officer, the Company entered into an employment agreement with Mr. Hoffman, pursuant to which he will receive an annual base salary of $200,000. The Company also accepted the resignation of Michael Kraft as President. Mr. Kraft will remain associated with the Company in the role of Senior Advisor. On October 21, 2022 an investor provided notice of cash exercise for pre-funded warrants with a price per share of $0.0001. The warrant exercise results in an issuance of 10,300,000 common shares for cash consideration of $1,030.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangibles
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Current assets and current liabilities Notes payable
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Loss Per Common Share September 30, 2022 2021 Options 53,158,160 53,711,609 Warrants 142,814,000 142,604,000 Series A convertible preferred stock 115,000 115,000 Convertible debt 45,155,537 40,914,134 Total potentially dilutive shares 241,242,697 237,344,743
Research and Development Expense, Policy [Policy Text Block]	Research and Development
Subsequent Events, Policy [Policy Text Block]	Subsequent Events
Income Tax, Policy [Policy Text Block]	Income Taxes
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2022 2021 Options 53,158,160 53,711,609 Warrants 142,814,000 142,604,000 Series A convertible preferred stock 115,000 115,000 Convertible debt 45,155,537 40,914,134 Total potentially dilutive shares 241,242,697 237,344,743

Note 3 - Intangibles (Tables)

Note 3 - Intangibles (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, December 31, Patents 2022 2021 Gross Carrying Amount $ 1,400,000 $ 1,400,000 Accumulated Amortization (481,375 ) (421,203 ) $ 918,625 $ 978,797

Note 4 - Notes Payable (Tables)

Note 4 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	September 30, December 31, 2022 2021 Notes payable: 5.26% Insurance premium finance agreement due June 2023 $ 91,498 $ - Notes payable - current $ 91,498 $ - Long term debt: 10% Promissory note due January 2024 $ 1,485,617 $ 1,310,617 Less: Warrants issued (63,684 ) (93,929 ) Debt issue costs (23,373 ) (29,171 ) Total long term debt $ 1,398,560 $ 1,187,518

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Warrant Activity [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2021 142,604,000 $ 0.0515 Granted 210,000 0.0520 Outstanding, September 30, 2022 142,814,000 $ 0.0515 3.89 $ 1,333,850
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2021 53,711,609 $ 0.093 Options granted 950,000 0.055 Options expired (3,449 ) 70.260 Exchanged for common stock (1,500,000 ) 0.041 Outstanding, September 30, 2022 53,158,160 $ 0.089 3.48 $ - Exercisable, September 30, 2022 53,158,160 $ 0.089 3.48 $ -
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 0.041 12,500,000 1.85 12,500,000 $ 0.055 950,000 4.48 950,000 $ 0.065 1,000,000 2.75 1,000,000 $ 0.105 38,500,000 4.00 38,500,000 $ 0.240 208,160 4.47 208,160 Total 53,158,160 3.48 53,158,160

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill, Impairment Loss	$ 0

Note 2 - Business and Summary o

Note 2 - Business and Summary of Significant Accounting Policies - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
potentially dilutive shares (in shares)	241,242,697	237,344,743
Options [Member]
potentially dilutive shares (in shares)	53,158,160	53,711,609
Warrant [Member]
potentially dilutive shares (in shares)	142,814,000	142,604,000
Series A Convertible Preferred Stock [Member]
potentially dilutive shares (in shares)	115,000	115,000
Convertible Debt Securities [Member]
potentially dilutive shares (in shares)	45,155,537	40,914,134

Note 3 - Intangibles (Details T

Note 3 - Intangibles (Details Textual) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Ending Balance	$ 927,632	$ 989,604
Patents [Member]
Finite-Lived Intangible Asset, Expected Amortization, Year One	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Two	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Three	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Four	80,000
Finite-Lived Intangible Asset, Expected Amortization, Year Five	80,000
Finite-Lived Intangible Asset, Expected Amortization, after Year Five	80,000
Finite-Lived Intangible Assets, Net, Ending Balance	918,625	978,797
Finite-Lived Intangible Assets, Accumulated Amortization	481,375	421,203
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Asset, Expected Amortization, Year One	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Two	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Three	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Four	2,400
Finite-Lived Intangible Asset, Expected Amortization, Year Five	2,400
Finite-Lived Intangible Assets, Net, Ending Balance		12,007
Finite-Lived Intangible Assets, Accumulated Amortization	$ 3,000	$ 1,200

Note 3 - Intangibles - Schedule

Note 3 - Intangibles - Schedule of Patents (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Ending Balance	$ 927,632	$ 989,604
Patents [Member]
Gross Carrying Amount	1,400,000	1,400,000
Accumulated Amortization	(481,375)	(421,203)
Finite-Lived Intangible Assets, Net, Ending Balance	$ 918,625	$ 978,797

Note 4 - Notes Payable (Details

Note 4 - Notes Payable (Details Textual)		1 Months Ended	9 Months Ended		12 Months Ended
	Oct. 04, 2019 USD ($) $ / shares shares	Aug. 31, 2022 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 $ / shares shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.0515			$ 0.0515
Class of Warrant or Right, Outstanding (in shares) | shares			142,814,000			142,604,000
Amortization Associated With Commitment Fee			$ 11,048	$ 11,978
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.052
Class of Warrant or Right, Outstanding (in shares) | shares			2,814,000
Class of Warrant or Right, Issued During Period (in shares) | shares			210,000
Allocated Cost of Warrants					$ 62,784
Amortization Expense Associated With Warrants			$ 34,346	$ 35,358
Insurance Financing Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage			5.26%
Debt Instrument, Face Amount			$ 101,444
Debt Instrument, Periodic Payment, Total		$ 10,391	$ 10,391
Three Point Eight Percent Insurance Premium Finance Agreement [Member]
Debt Instrument, Term (Year)			10 years
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage	10%		10%		10%
Debt Agreement, Maximum Borrowing Capacity	$ 2,500,000
Debt Instrument, Number of Tranches	16
Proceeds from Notes Payable, Total			$ 2,345,000
Debt Instrument, Notes Payable, Portion Not Advanced			155,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	70%
Debt Instrument, Convertible, Threshold Trading Days	15
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.0329
Line of Credit Facility, Commitment Fee Percentage	3%
Line of Credit Facility, Commitment Fee and Debt-related Expenses to Be Amortized			5,250		$ 10,350
Credit Agreement And Note [Member] | Minimum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche	$ 125,000
Credit Agreement And Note [Member] | Maximum [Member]
Debt Instrument, Amount Funded in Each Monthly Tranche	$ 175,000
Warrant Issued in Connection With Credit Agreement [Member]
Allocated Cost of Warrants			$ 4,101

Note 4 - Debt - Schedule of Deb

Note 4 - Debt - Schedule of Debt (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Notes payable	$ 91,498	$ 0
Total long term debt	1,398,560	1,187,518
Credit Agreement And Note [Member]
10% Promissory note due January 2024	1,485,617	1,310,617
Warrants issued	(63,684)	(93,929)
Debt issue costs	$ (23,373)	$ (29,171)

Note 4 - Debt - Schedule of D_2

Note 4 - Debt - Schedule of Debt-parentheticals (Details) (Parentheticals)	Sep. 30, 2022	Dec. 31, 2021	Oct. 04, 2019
Insurance Financing Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage	5.26%
Credit Agreement And Note [Member]
Debt Instrument, Interest Rate, Stated Percentage	10%	10%	10%

Note 5 - Commitments and Cont_3

Note 5 - Commitments and Contingencies (Details Textual)					9 Months Ended
	Mar. 23, 2022 $ / shares shares	Mar. 02, 2021 USD ($) $ / shares shares	Jun. 08, 2020 shares	Oct. 04, 2019 $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	May 01, 2022 USD ($)	Dec. 14, 2021 USD ($)	Dec. 31, 2020 $ / shares shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.0515				$ 0.0515
Class of Warrant or Right, Issued Monthly (in shares)					210,000
Class of Warrant or Right, Outstanding (in shares)					142,814,000				142,604,000
Share Exchange Agreement, Number of Options Authorized (in shares)			21,500,000
Share Exchange Agreement, Exchange Ratio			0.6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exchanged (in shares)					1,500,000
Stock Issued During Period, Shares, Stock Options Exchanged for Common Shares (in shares)					900,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	950,000				950,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 0.055
Operating Lease, Expense | $					$ 29,952	$ 11,340
Lease for Dedicated Office Space [Member]
Lessee, Operating Lease, Liability, to be Paid, Total | $							$ 42,000
Ann Arbor, Michigan [Member] | Building, Wet laboratory [Member]
Lessee, Operating Lease, Liability, to be Paid, Total | $								$ 12,600
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		23,500,000
Proceeds from Issuance or Sale of Equity, Total | $		$ 6,000,000
Warrant Issued in Connection With Credit Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				3,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.052
Class of Warrant or Right, Number of Warrants Issued Per Dollar in the Event of Funding Deviation (in shares)				1.2
Class of Warrant or Right, Outstanding (in shares)					2,814,000
Warrant Issued in Connection With Credit Agreement [Member] | Minimum [Member]
Class of Warrant or Right, Issued Monthly (in shares)				150,000
Warrant Issued in Connection With Credit Agreement [Member] | Maximum [Member]
Class of Warrant or Right, Issued Monthly (in shares)				210,000
Pre-funded Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		51,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.0001
Class of Warrant or Right, Purchase Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.08
Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		82,500,000
Class of Warrant or Right, Purchase Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.0799
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					6,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.10
Warrants Ownership Percentage, Maximum Limit		8%

Note 5 - Commitments and Cont_4

Note 5 - Commitments and Contingencies - Warrants (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Granted, number of warrants (in shares) | shares	210,000
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.0520
Outstanding, number of warrants (in shares) | shares	142,814,000
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.0515
Outstanding, weighted-average remaining life (Year)	3 years 10 months 20 days
Outstanding, aggregate intrinsic value | $	$ 1,333,850

Note 5 - Commitments and Cont_5

Note 5 - Commitments and Contingencies - Option Activity (Details) - USD ($)			9 Months Ended
	Sep. 30, 2022	Mar. 23, 2022	Sep. 30, 2022
Options granted (in shares)		950,000	950,000
Granted, Weighted Average Exercise Price (in dollars per share)			$ 0.055
Exchanged for common stock (in shares)			(1,500,000)
Exercisable (in shares)	53,158,160		53,158,160
Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0.089		$ 0.089
Exercisable, Weighted Average Remaining Life (Year)	3 years 5 months 23 days
Exercisable, Aggregate intrinsic value	$ 0		$ 0
Share-Based Payment Arrangement, Option [Member]
Outstanding (in shares)			53,711,609
Outstanding, Weighted Average Exercise Price (in dollars per share)			$ 0.093
Options expired (in shares)			(3,449)
Options expired, Weighted Average Exercise Price (in dollars per share)			$ 70.260
Exchanged for common stock (in shares)			(1,500,000)
Exchanged for common stock, Weighted Average Exercise Price (in dollars per share)			$ 0.041
Outstanding (in shares)	53,158,160		53,158,160
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.089		$ 0.089
Outstanding, Weighted Average Remaining Life in Years (Year)			3 years 5 months 23 days
Outstanding, Aggregate intrinsic value	$ 0		$ 0

Note 5 - Commitments and Cont_6

Note 5 - Commitments and Contingencies - Shares Authorized Under Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Exercise Price Range One [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.041
Option Outstanding, Number Of Options (in shares)	12,500,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	1 year 10 months 6 days
Option Exercisable, Number Of Options (in shares)	12,500,000
Exercise Price Range Two [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.055
Option Outstanding, Number Of Options (in shares)	950,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 5 months 23 days
Option Exercisable, Number Of Options (in shares)	950,000
Exercise Price Range Three [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.065
Option Outstanding, Number Of Options (in shares)	1,000,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	2 years 9 months
Option Exercisable, Number Of Options (in shares)	1,000,000
Exercise Price Range Four [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.105
Option Outstanding, Number Of Options (in shares)	38,500,000
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years
Option Exercisable, Number Of Options (in shares)	38,500,000
Exercise Price Range Five [Member]
Option Outstanding, Exercise Price (in dollars per share) | $ / shares	$ 0.240
Option Outstanding, Number Of Options (in shares)	208,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	4 years 5 months 19 days
Option Exercisable, Number Of Options (in shares)	208,160
Exercise Price Range Six [Member]
Option Outstanding, Number Of Options (in shares)	53,158,160
Option Exercisable, Weighted Average Remaining Life In Years (Year)	3 years 5 months 23 days
Option Exercisable, Number Of Options (in shares)	53,158,160

Note 6 - Subsequent Events (Det

Note 6 - Subsequent Events (Details Textual) - USD ($)					9 Months Ended
	Oct. 21, 2022	Oct. 18, 2022	Oct. 14, 2022	Mar. 23, 2022	Sep. 30, 2022	Mar. 02, 2021	Dec. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				950,000	950,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 0.055
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.0515		$ 0.0515
Pre-funded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 0.0001
Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			24,000,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.0277
Subsequent Event [Member] | Pre-funded Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001
Stock Issued During Period, Shares, Warrants Exercised	10,300,000
Proceeds from Warrant Exercises	$ 1,030
Subsequent Event [Member] | Co-chairman, Victor Keen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			3,000,000
Subsequent Event [Member] | Co-chairman, Simon Calton [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			3,000,000
Subsequent Event [Member] | Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			7,000,000
Subsequent Event [Member] | Chief Financial Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			5,000,000
Subsequent Event [Member] | Employees and Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			6,000,000
Subsequent Event [Member] | Chief Operating Officer [Member]
Annual Base Salary		$ 200,000
Subsequent Event [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period			5 years